SHOCKWAVE MEDICAL, INC.

(SWAV)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
174.33 USD   +3.36%
05/23SECTOR UPDATE : Health Care Stocks Moderating in Late Trade
MT
05/23SECTOR UPDATE : Health Care Stocks Rising in Monday Trading
MT
05/23SECTOR UPDATE : Health Care
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
165.57(c) 160.69(c) 166.78(c) 168.67(c) 174.33(c) Last
468 240 315 339 249 813 298 011 211 726 Volume
+4.61% -2.95% +3.79% +1.13% +3.36% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 448 M - -
Net income 2022 77,4 M - -
Net cash position 2022 230 M - -
P/E ratio 2022 85,7x
Yield 2022 -
Sales 2023 582 M - -
Net income 2023 112 M - -
Net cash position 2023 371 M - -
P/E ratio 2023 60,6x
Yield 2023 -
Capitalization 6 240 M 6 240 M -
EV / Sales 2022 13,4x
EV / Sales 2023 10,1x
Nbr of Employees 657
Free-Float 94,1%
More Financials
Company
Shockwave Medical, Inc. is a medical device company. The Company is engaged in medical device treatment of atherosclerotic cardiovascular disease (atherosclerosis) through its differentiated local delivery of sonic pressure waves for the treatment of calcified plaque, which refer to as intravascular lithotripsy (IVL). Its products for the treatment of peripheral artery disease (PAD) includes Shockwave M5 IVL... 
More about the company
Ratings of ShockWave Medical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SHOCKWAVE MEDICAL, INC.
05/23SECTOR UPDATE : Health Care Stocks Moderating in Late Trade
MT
05/23SECTOR UPDATE : Health Care Stocks Rising in Monday Trading
MT
05/23SECTOR UPDATE : Health Care
MT
05/23ShockWave Medical Receives Chinese Approval to Market Intravascular Lithotripsy System
MT
05/23TRANSCRIPT : ShockWave Medical, Inc. Presents at UBS Global Healthcare Conference, May-23-..
CI
05/23Shockwave Medical and Genesis MedTech Obtain Regulatory Approval in China for Intravasc..
GL
05/23Shockwave Medical and Genesis MedTech Obtain Regulatory Approval in China for Intravasc..
GL
05/23Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from Ch..
CI
05/19Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at T..
GL
05/19Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at T..
AQ
05/19Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At T..
CI
05/19Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men..
GL
05/19Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men..
GL
05/19Shockwave Medical, Inc. Announces New Data Confirming Excellent One-Year Outcomes with ..
CI
05/13INSIDER SELL : Shockwave Medical
MT
More news
News in other languages on SHOCKWAVE MEDICAL, INC.
05/23MISE À JOUR SECTORIELLE : Les actions du secteur de la santé se modèrent en fin de séance
05/23MISE À JOUR SECTORIELLE : Les actions du secteur des soins de santé en hausse ce lundi
05/23MISE À JOUR SECTORIELLE : Soins de santé
05/23ShockWave Medical reçoit l'approbation de la Chine pour commercialiser un système de li..
05/23Shockwave Medical, Inc. et Genesis MedTech Group ont obtenu l'approbation de l'Administ..
More news
Analyst Recommendations on SHOCKWAVE MEDICAL, INC.
More recommendations
Chart SHOCKWAVE MEDICAL, INC.
Duration : Period :
ShockWave Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHOCKWAVE MEDICAL, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 174,33 $
Average target price 190,86 $
Spread / Average Target 9,48%
EPS Revisions
Managers and Directors
Douglas Evan Godshall President, Chief Executive Officer & Director
Daniel Puckett Chief Financial Officer & Secretary
C. Raymond Larkin Chairman
Beaux Alexander Vice President-Clinical Affairs
W. Patrick Stephens Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
SHOCKWAVE MEDICAL, INC.-2.24%6 240
NOVOCURE LIMITED11.85%8 783
MASIMO CORPORATION-50.99%7 965
GETINGE AB-29.13%7 752
PENUMBRA, INC.-48.01%5 628
IRAY TECHNOLOGY COMPANY LIMITED-24.87%4 043